1986
DOI: 10.1001/jama.1986.03380060070028
|View full text |Cite
|
Sign up to set email alerts
|

Prevention of Venous Thrombosis and Pulmonary Embolism

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0

Year Published

1998
1998
2023
2023

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 450 publications
(3 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…Considerations for treatment: Pregnant women are five times more likely to experience thromboembolic events than non-pregnant women due to their hypercoagulable status. This danger is related to a hypercoagulable state and venous stasis in the lower extremities brought on by the growing fetus in the womb compressing the inferior vena cava 3,23 . For pregnant women with a history of thromboembolic disease, anticoagulant prophylaxis in the form of low molecular weight heparin is advised to prevent this issue.…”
Section: Hematologic Changesmentioning
confidence: 99%
“…Considerations for treatment: Pregnant women are five times more likely to experience thromboembolic events than non-pregnant women due to their hypercoagulable status. This danger is related to a hypercoagulable state and venous stasis in the lower extremities brought on by the growing fetus in the womb compressing the inferior vena cava 3,23 . For pregnant women with a history of thromboembolic disease, anticoagulant prophylaxis in the form of low molecular weight heparin is advised to prevent this issue.…”
Section: Hematologic Changesmentioning
confidence: 99%
“…50 The risk of venous thromboembolism is 5x higher in pregnant patients compared to non-pregnant patients. 51,52 Current recommendations for DVT prophylaxis include intraoperative and postoperative pneumatic compression devices, as well as early ambulation. 35 There is limited research regarding the use of chemical prophylaxis in pregnant patients, particularly unfractionated or low-molecular-weight heparin, but heparin can be safely used with monitoring because it does not cross the placenta.…”
Section: Dovepressmentioning
confidence: 99%
“…The cumulative event rate exceeds 10% by 80 years of age [2] and is associated with substantial mortality and morbidity in the absence of treatment [3]. Clinical symptoms are usually not sufficiently specific for the establishment or exclusion of diagnosis [4]. Objective testing is required to verify clinical suspicion.…”
Section: Introductionmentioning
confidence: 99%